{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:21:15Z","timestamp":1792239675314,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007726","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T00:00:00Z","timestamp":1364428800000}}],"reference-count":59,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007726.pub2","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T17:28:36Z","timestamp":1364578116000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia"],"prefix":"10.1002","author":[{"given":"Tom","family":"Declercq","sequence":"first","affiliation":[{"name":"Ghent University; Department of General Practice and Primary Health Care; De Pintelaan 185, UZ-6K3 Ghent Belgium B-9000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Petrovic","sequence":"additional","affiliation":[{"name":"Ghent University Hospital; Department of Geriatrics; De Pintelaan 185, UZ-1K2 Ghent Belgium B-9000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majda","family":"Azermai","sequence":"additional","affiliation":[{"name":"Ghent University; Heymans Institute of Pharmacology; Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vander Stichele","sequence":"additional","affiliation":[{"name":"Heymans Institute of Pharmacology; Ghent University Ghent Belgium B-9000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An IM","family":"De Sutter","sequence":"additional","affiliation":[{"name":"Ghent University; Department of General Practice and Primary Health Care; De Pintelaan 185, UZ-6K3 Ghent Belgium B-9000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke L","family":"van Driel","sequence":"additional","affiliation":[{"name":"The University of Queensland; Discipline of General Practice, School of Medicine; Brisbane Queensland Australia 4006"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Christiaens","sequence":"additional","affiliation":[{"name":"Ghent University; Department of General Practice and Primary Health Care; De Pintelaan 185, UZ-6K3 Ghent Belgium B-9000"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,28]]},"reference":[{"key":"10.1002\/14651858.CD007726.pub2-BIB0001|cit1","unstructured":"Ballard C A randomised double blind placebo controlled trial to compare the progression of cognitive impairment in dementia patients continuing to take or discontinued from neuroleptic treatment National Research Register 2003b"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0002|cit2","unstructured":"Ballard C A randomised, double blind, placebo-controlled clinical trial to compare the progression of cognitive impairment in dementia patients continuing to take, or discontinued from, treatment with neuroleptics ISRCTN Register 2006"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4088\/JCP.v65n0120","article-title":"A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the Neuropsychiatric Inventory median cutoff is a predictor of clinical outcome","volume":"65","author":"Ballard","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0004|cit4","unstructured":"Ballard J Stopping neuroleptics: does it improve the quality of life for people with dementia National Research Register 2000"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0005|cit5","unstructured":"Fossey J Ballard C Stopping neuroleptics: does it improve quality of life for people with dementia National Research Register 2003"},{"issue":"2","key":"10.1002\/14651858.CD007726.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial","volume":"8","author":"Ballard","year":"2009","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007726.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1371\/journal.pmed.0050076","article-title":"A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)","volume":"5","author":"Ballard","year":"2008","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/089198879701000306","article-title":"Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study","volume":"10","author":"Bridges-Parlet","year":"1997","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0009|cit9","volume-title":"The Effect of Neuroleptic Withdrawal on Physically Aggressive Behaviour in Dementia [Dissertation]","author":"Bridges-Parlet","year":"1996"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.159.15.1733","article-title":"Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home","volume":"159","author":"Cohen-Mansfield","year":"1999","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0011|cit11","unstructured":"Cohen-Mansfield J Lipson S Werner P Billig N Woosley R Discontinuation of psychotropic drugs in the nursing home: a double blind controlled study Proceedings of the 12th International Conference on Alzheimer's Disease and Related Disorders, 1996 Oct 8-11, Jerusalem 1996"},{"issue":"9","key":"10.1002\/14651858.CD007726.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.2630","article-title":"A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease","volume":"26","author":"Devanand","year":"2011","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"16","key":"10.1002\/14651858.CD007726.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","article-title":"Relapse risk after discontinuation of risperidone in Alzheimer's disease","volume":"367","author":"Devanand","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gps.930040210","article-title":"Double-blind controlled withdrawal of thioridazine treatments in elderly female inpatients with senile dementia","volume":"4","author":"Findlay","year":"1989","journal-title":"International Journey of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/gps.1998","article-title":"Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study - the Bergen District Nursing Home Study (BEDNURS)","volume":"23","author":"Ruths","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1532-5415.2004.52470.x","article-title":"Effect of antipsychotic withdrawal on behavior and sleep\/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen district nursing home study","volume":"52","author":"Ruths","year":"2004","journal-title":"Journal of American Geriatric Society"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1041610202008396","article-title":"A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia","volume":"14","author":"Reekum","year":"2002","journal-title":"International Psychogeriatrics"},{"issue":"4","key":"10.1002\/14651858.CD007726.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00019442-199503040-00003","article-title":"Discontinuation of antipsychotics in nursing home patients with dementia","volume":"3","author":"Horwitz","year":"1995","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD007726.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/gps.930071009","article-title":"Prolactin response to withdrawal of thioridazine in dementia","volume":"7","author":"McLennan","year":"1992","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0020|cit20","unstructured":"Rule S A randomised double blind placebo controlled clinical trial to compare the progression of cognitive impairment in dementia patients continuing to take or discontinued from treatment with typical neuroleptics National Research Register 2003"},{"issue":"6","key":"10.1002\/14651858.CD007726.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/JCP.0b013e3181fa05bb","article-title":"Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease trial","volume":"30","author":"Wessels","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD007726.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1017\/S1041610211000421","article-title":"A 12-month follow-up study of \"REDuse\": a trial aimed at reducing antipsychotic and benzodiazepine use in nursing homes","volume":"23","author":"Westbury","year":"2011","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0023|cit23","unstructured":"Engedal K Bergh S Discontinuation of antipsychotics and antidepressants among patients with dementia and BPSD living in nursing homes - a 24 weeks double blind RCT clinicaltrials.gov\/ct2\/show\/NCT00594269"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hup.1160","article-title":"Geriatric drug utilisation of psychotropics in Belgian nursing homes","volume":"26","author":"Azermai","year":"2011","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD007726.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003476.pub2","article-title":"Atypical antipsychotics for aggression and psychosis in Alzheimer's disease","author":"Ballard","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1371\/journal.pmed.0050076","article-title":"A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)","volume":"5","author":"Ballard","year":"2008","journal-title":"PLoS Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007726.pub2-BIB0027|cit27","first-page":"729","article-title":"Management of neuropsychiatric symptoms in people with dementia","volume":"24","author":"Ballard","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0028|cit28","unstructured":"Banerjee S The use of antipsychotic medication for people with dementia: time for action. A Report for the Minister of State for Care Services by Professor Sube Banerjee London: The Stationary Office 2009"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archinte.165.11.1280","article-title":"The quality of antipsychotic drug prescribing in nursing homes","volume":"165","author":"Briesacher","year":"2005","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0030|cit30","unstructured":"Canadian Agency for Drugs and Technologies in Health Short-acting benzodiazepines versus other strategies for the management of agitation in older patients: clinical effectiveness and guidelines, 2010 www.cadth.ca\/media\/pdf\/k0209_managing_agitation_older_patients_htis_1-5.pdf"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/gps.2275","article-title":"Non-pharmacological management of behavioural symptoms in nursing homes","volume":"24","author":"Deudon","year":"2009","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD007726.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/JGP.0b013e3182110563","article-title":"The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design","volume":"20","author":"Devanand","year":"2012","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0033|cit33","unstructured":"US Food and Drug Administration Public Health Advisory Deaths with antipsychotics in elderly patients with behavioral disturbances www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/PublicHealthAdvisories\/ucm053171.htm"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0034|cit34","unstructured":"US Food and Drug Administration Public Health Advisory Antipsychotics are not indicated for the treatment of dementia-related psychosis www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htm"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: a Delphi consensus study","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0036|cit36","first-page":"497","article-title":"Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment","volume":"8 Suppl 3","author":"Finkel","year":"1996","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/gps.1341","article-title":"Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the neuropsychiatric inventory (NPI) data of two randomised, controlled studies","volume":"20","author":"Gauthier","year":"2005","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD007726.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1017\/S1041610209991505","article-title":"Management of behavioral problems in Alzheimer's disease","volume":"22","author":"Gauthier","year":"2010","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1017\/S1041610200006785","article-title":"Are behavioral and psychological symptoms of dementia associated with mortality in Alzheimer's disease?","volume":"12","author":"Gilley","year":"2000","journal-title":"International Psychogeriatrics"},{"issue":"10","key":"10.1002\/14651858.CD007726.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/gps.1594","article-title":"The contribution of neuropsychiatric symptoms to the cost of dementia care","volume":"21","author":"Herrmann","year":"2006","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0041|cit41","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa066583","article-title":"Donepezil for the treatment of agitation in Alzheimer's disease","volume":"357","author":"Howard","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1136\/bmj.e977","article-title":"Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study","volume":"344","author":"Huybrechts","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0044|cit44","first-page":"18","article-title":"Primary care physicians guide to behavioral and psychological symptoms of dementia","volume-title":"Primary care physicians guide to behavioral and psychological symptoms of dementia","author":"Anonymous","year":"2003"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1136\/bmj.e1093","article-title":"Antipsychotic prescribing in nursing homes","volume":"344","author":"McCleery","year":"2012","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD007726.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1532-5415.1997.tb04509.x","article-title":"Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education","volume":"45","author":"Meador","year":"1997","journal-title":"Journal of the American Geriatric Society"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1744-859X-4-18","article-title":"Primary care use of antipsychotic drugs: an audit and intervention study","volume":"4","author":"Mortimer","year":"2005","journal-title":"Annals of General Psychiatry"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0048|cit48","unstructured":"National Institute for Health and Clinical Excellence Dementia guidance.nice.org.uk\/CG42"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"a602","DOI":"10.1136\/bmj.a602","article-title":"Antipsychotics for people with dementia","volume":"337","author":"O'Brien","year":"2008","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD007726.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/ncpneuro0884","article-title":"Neuroleptics discontinuation during dementia care: a recent trial and its implications for practice","volume":"4","author":"Onyike","year":"2008","journal-title":"Nature Clinical Practice Neurology"},{"issue":"6","key":"10.1002\/14651858.CD007726.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1179\/acb.2007.062","article-title":"Clustering of behavioural and psychological symptoms in dementia (BPSD): a European Alzheimer's Disease in Consortium (EADC) Study","volume":"62","author":"Petrovic","year":"2007","journal-title":"Acta Clinica Belgica"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0052|cit52","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.eurpsy.2004.09.031","article-title":"Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer Disease Consortium","volume":"20","author":"Robert","year":"2005","journal-title":"European Psychiatry"},{"issue":"15","key":"10.1002\/14651858.CD007726.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomised, placebo-controlled trials","volume":"14","author":"Schneider","year":"2006","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.293.5.596","article-title":"Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence","volume":"293","author":"Sink","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD007726.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/ebmh1159","article-title":"Antipsychotics in dementia - mortality risks and strategies to reduce prescribing","volume":"14","author":"Smith","year":"2011","journal-title":"Evidence Based Mental Health"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Vander Stichele R Van de Voorde C Elseviers M Verrue C Soenen K Smet M Medication use in Belgian nursing homes, 2006 kce.fgov.be\/publication\/report\/medication-use-in-rest-and-nursing-homes-in-belgium","DOI":"10.57598\/R47C"},{"key":"10.1002\/14651858.CD007726.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/0891988706292762","article-title":"Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients","volume":"20","author":"Zuidema","year":"2007","journal-title":"Journal of Geriatric Psychiatry and Neurology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007726.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007726.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T22:37:53Z","timestamp":1745966273000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007726.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,28]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007726.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718006506.793477811","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,28]]}}}